We are live on ! Find out more
BVS icon

Bioventus

135 hedge funds and large institutions have $329M invested in Bioventus in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 40 increasing their positions, 50 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 24

3% more capital invested

Capital invested by funds: $320M → $329M (+$8.63M)

1% more funds holding

Funds holding: 134135 (+1)

0.59% more ownership

Funds ownership: 72.92%73.51% (+0.59%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

20% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 50

48% less call options, than puts

Call options by funds: $350K | Put options by funds: $669K

Holders
135
Holders Change
+1
Holders Change %
+0.75%
% of All Funds
1.77%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
26
Increased
40
Reduced
50
Closed
24
Calls
$350K
Puts
$669K
Net Calls
-$319K
Net Calls Change
-$828K
Name Holding Trade Value Shares
Change
Change in
Stake
Marshall Wace
26
Marshall Wace
United Kingdom
$1.92M +$527K +75,924 +36%
Jane Street
27
Jane Street
New York
$1.84M +$1.91M +274,911 New
BNP Paribas Financial Markets
28
BNP Paribas Financial Markets
France
$1.66M +$749K +107,934 +77%
Morgan Stanley
29
Morgan Stanley
New York
$1.63M -$2.84M -409,162 -63%
Two Sigma Investments
30
Two Sigma Investments
New York
$1.37M +$1.42M +205,026 New
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$1.26M +$822K +118,450 +168%
Mariner
32
Mariner
Kansas
$1.09M +$71.5K +10,303 +7%
Squarepoint
33
Squarepoint
New York
$988K +$275K +39,628 +37%
N
34
Nuveen
North Carolina
$985K -$271K -39,007 -21%
Jacobs Levy Equity Management
35
Jacobs Levy Equity Management
New Jersey
$943K +$32K +4,605 +3%
AFS
36
Anderson Financial Strategies
Ohio
$901K +$935K +134,720 New
Lazard Asset Management
37
Lazard Asset Management
New York
$897K +$411K +59,202 +79%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$881K -$24.3K -3,507 -3%
Connor, Clark & Lunn Investment Management (CC&L)
39
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$848K -$338K -48,725 -28%
BFM
40
Boothbay Fund Management
New York
$782K +$230K +33,117 +40%
JP Morgan Chase
41
JP Morgan Chase
New York
$768K -$895K -128,933 -53%
Franklin Resources
42
Franklin Resources
California
$681K -$204K -29,363 -22%
Two Sigma Advisers
43
Two Sigma Advisers
New York
$648K +$564K +81,200 +516%
Envestnet Asset Management
44
Envestnet Asset Management
Illinois
$589K -$23.4K -3,367 -4%
Comerica Bank
45
Comerica Bank
Texas
$589K
GC
46
Globeflex Capital
California
$516K -$91.3K -13,151 -15%
UBS Group
47
UBS Group
Switzerland
$481K -$109K -15,653 -18%
Los Angeles Capital Management
48
Los Angeles Capital Management
California
$474K -$353K -50,929 -42%
XT
49
XTX Topco
Cayman Islands
$474K +$492K +70,894 New
Barclays
50
Barclays
United Kingdom
$441K -$154K -22,132 -25%

BVS Hedge Fund Activity: Q3 2025 in Review

135 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q3 2025, worth a combined $329M — up 2.7% from $320M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BVS positions and 24 closed out — a net gain of 2 holders — while 40 added to existing stakes and 50 trimmed.

The largest buyer was Kent Lake PR, adding an estimated $4.51M. The largest seller was Millennium Management, cutting an estimated $3.92M.

  • 135 institutional investors held Bioventus (BVS) as of Q3 2025, up from 134 in Q2 2025.
  • Funds reported $329M of Bioventus stock for Q3 2025, up 2.7% quarter-over-quarter.
  • 26 funds opened new Bioventus positions in Q3 2025 and 24 closed out, a net change of +2 holders.
  • The largest Bioventus buyer in Q3 2025 was Kent Lake PR, an estimated $4.51M added.
  • The largest Bioventus seller in Q3 2025 was Millennium Management, an estimated $3.92M sold.

Based on aggregated 13F filings for Q3 2025.